89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at Evercore ISI from $37.00 to $33.00. They now have an "outperform" rating on the stock.
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis [Yahoo! Finance]
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at HC Wainwright from $31.00 to $29.00. They now have a "buy" rating on the stock.